Myomo (NYSEAMERICAN:MYO) Insider Harry Kovelman Sells 20,464 Shares

Myomo, Inc. (NYSEAMERICAN:MYO) insider Harry Kovelman sold 20,464 shares of the stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $1.00, for a total transaction of $20,464.00. Following the completion of the sale, the insider owned 120,154 shares in the company, valued at approximately $120,154. This trade represents a 14.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Harry Kovelman also recently made the following trade(s):

• On Thursday, May 28th, Harry Kovelman sold 11,536 shares of Myomo stock. The stock was sold at an average price of $1.02, for a total transaction of $11,766.72.

Myomo Stock Performance

MYO opened at $1.09 on Friday. The firm’s fifty day moving average is $0.81 and its two-hundred day moving average is $0.85. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.36 and a current ratio of 2.73. The firm has a market cap of $42.12 million, a PE ratio of -3.03 and a beta of 1.39. Myomo, Inc. has a twelve month low of $0.61 and a twelve month high of $3.14.

Institutional Investors Weigh In On Myomo

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Engineers Gate Manager LP increased its stake in Myomo by 62.8% in the 2nd quarter. Engineers Gate Manager LP now owns 30,097 shares of the company’s stock valued at $65,000 after buying an additional 11,614 shares during the last quarter. Bank of America Corp DE increased its stake in Myomo by 93.6% in the 3rd quarter. Bank of America Corp DE now owns 30,412 shares of the company’s stock valued at $27,000 after buying an additional 14,705 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Myomo in the 1st quarter valued at $75,000. Invesco Ltd. acquired a new stake in Myomo in the 2nd quarter valued at $37,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Myomo in the 2nd quarter valued at $38,000. 44.99% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Craig Hallum restated a “buy” rating on shares of Myomo in a report on Tuesday, March 10th. Four research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $7.67.

Myomo Company Profile

Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.